Glenridge Pharmaceuticals is an emerging specialty pharmaceutical company focused on the licensing, acquisition, development, and commercialization of products that address critical need populations. More information concerning product opportunities and upcoming company activities will be posted soon.
JONES PHARMA INCORPORATED offers four products for the treatment of thyroid disease: Tapazole® (Methimazole Tablets, USP), Levoxyl® (Levothyroxine Sodium Tablets, USP), Cytomel® (Liothyronine Sodium Tablets) and Triostat® (Liothyronine Sodium Injection). JONES PHARMA INCORPORATED markets pharmaceuticals used in the operating room as well as other products used for emergency, rehabilatative and skin care: Thrombin-JMI® (Thrombin, Topical, Bovine, USP), Brevital® (Methohexital Sodium for Injection, USP), Liqui-Char® (Activated Charcoal, USP), Therevac® (The Mini Enema), Triostat® (Liothyronine Sodium Injection) and DERMA® Professional Skin Care products. JONES PHARMA INCORPORATED manufactures and distributes Veterinary Pharmaceuticals for companion animals. Soloxine® (levothyroxine sodium tablets, USP) is used for the treatment of hypothyroidism in small animals. Tumil-K® (potassium gluconate) is the leading treatment for feline hypokalemia. Pancrezyme® (pancreatic lipase, protease and amylase) is an economical alternative to Viokase®-V as a digestive aid where an exocrine pancreatic insufficiency exists. Uroeze® (ammonium chloride in a palatable base) is used to help maintain proper urinary pH in felines. Liqui-Char®-Vet (activated charcoal, USP) is designed for emergency treatment of ingested toxic substances. Therevac® SB (The "Mini-enema") is a fast-acting, non-irritating bowel care product. Professional Skin Care Products include DERMA SCRUB® creme soap, CHLOROSTAT® antimicrobial skin cleanser and surgical scrub, DERMA CIDOL® 2000 antimicrobial hand wash with skin conditioners, DERMA SOOTHE® professional skin lotion and DERMA STAT® antimicrobial waterless hand foam.
Valeant Canada is a specialty pharmaceutical company and is a subsidiary of Valeant Pharmaceuticals International. Valeant Canada manufactures and markets pharmaceuticals products, primarily in the areas of Neurology, Psychiatry, Pain Management and Dermatology. In 2006, Valeant Canada total revenues were $41.8 million (USD) that were generated by 39 products and more than 100 SKUs. Based in Montreal, Quebec, Valeant Canada employs 150 people.
Iqura is a leading provider of IT solutions meeting the challenging needs of customers in the global market. We go beyond the traditional definitions of consulting, by innovating to bring you solutions that dramatically improve the efficiencies in your business. Established in 1998 and headquartered in Bangalore, our customers range from start-ups to Fortune 500 corporations.
Halsey Drug Co., Inc., together with its subsidiaries, is an emerging pharmaceutical technology development company specializing in proprietary abuse deterrent formulation technology and opioid API synthesis technologies.
As a major supplier of therapeutic and diagnostic products, CIS-US, Inc. is dedicated to providing a foundation of products for the detection, treatment and monitoring of major human pathologies. CIS-US, Inc. envisions broad opportunities for new radiopharmaceutical diagnostic and therapeutic developments. Our pledge is to facilitate healthcare excellence for patients while maintaining the greatest value for healthcare professionals. To ensure that our pledge becomes a reality we are engaged in new product development and continuing investment in our cGMP manufacturing and testing capability. CIS-US, Inc. offers contract and private-label manufacturing services to firms requiring fully validated, aseptic processing for pharmaceutical diagnostic and therapeutic products.
Nascent Pharmaceuticals, Inc. is a privately held company funded by individual and institutional investors. Nascent's lead institutional investor is Advantage Capital Partners, a private equity firm. Since 1992 Advantage has raised more than $700 million in institutional capital and has invested in a wide variety of companies and real estate projects. The firm targets its investment activities in geographic areas that are underserved by venture capital.
Medicis AestheticsÔ is a subsidiary of Medicis, a well-established pharmaceutical company dedicated to helping patients attain a healthy and youthful appearance and self-image. And should you ever have any question about the use or administration of Restylane®, please contact us. We want to hear from you.
Dedicated to innovation in women's healthcare, Biotegrity is a specialty pharmaceutical company focusing on pharmaceutical solutions that specifically address the needs of women. In everything we do, people are the focus of our organization. From the patients who take our products to our exceptional group of associates, we are a company that is dedicated to the health and well-being of those we come into contact with.
Roberts Pharmaceutical Corporation, with operating subsidiaries in the United States, Canada and the United Kingdom, focuses on value-added specialty pharmaceuticals in the therapeutic categories of gastroenterology, urology, oncology/hematology, and cardiology/neurology. Roberts actively pursues its strategy of Search & Develop to identify and acquire novel post-discovery drug candidates to advance through late-stage clinical development while also pursuing opportunities to acquire and enhance the potential of commercially available specialty medicines.
EyeGate provides a stimulating work environment with career opportunities in both Europe and the U.S. We are looking for more great people to join our venture - specifically, high energy candidates with solid performance backgrounds, creative ideas and a commitment to excellence. Our cohesive environment fosters individual successes, as well as team accomplishments. If you share the same vision as we do at EyeGate Pharma and are interested in joining the EyeGate team, please forward your resume to hr@eyegatepharma.com.
BioSyent Inc. (BioSyent) is a life science company that acquires or licenses products and commercializes science-based technologies that advance human health and public safety. The Company, through its subsidiary, BioSyent Pharma Inc., has launched FeraMAX, an oral hematinic, to the Canadian healthcare market. FeraMAX is indicated for the prevention and treatment of iron deficiency anaemia. BioSyent manufactures and markets two: Protect-It and Insecolo. Protect-It is a non-chemical, food-safe grain insecticide. The formula contains a natural mineral called diatomaceous earth (DE). Protect-It is used as a preventative treatment against insect infestations in stored grains. It is registered for use in Canada, the United States, Croatia and Syria. Insecolo is a natural insecticide for home and garden use made from a formula of DE and food grade additives. It is registered for use in Canada and is marketed by SC Johnson and Son Limited under the Raid Earthblends Ant & Earwig Dust brand. (Source: ARS)
Navamedic ASA, former Glucomed ASA, is a Norway-based pharmaceutical company, focusing on the development, production and marketing of glucosamine hydro-chloride (HCI) based medicines. Its main product is Glucomed, a glucosamine based painkiller for patients with osteoarthritis. The Company markets Glucomed through its partners in the Nordic countries, Russia, the Czech Republic, Ukraine, Belarus, Poland, Slovakia, Kazakhstan, Spain, Switzerland, the United Kingdom, Portugal, Greece, Cyprus and Korea. Navamedic ASA is headquartered in Lysaker, Norway.
Barbeau Pharma, Inc., located in Evanston, Illinois, develops, gains marketing approval and markets or out-licenses specialty ethical pharmaceuticals. The company pursues the development and regulatory approval of drugs currently on the market which no longer enjoy patent protection and which are experiencing substantial off-label use for patient treatments. With several drugs under development, Barbeau identifies new opportunities for existing, off-patent therapeutics through a strategy of development for new indications that will also have the advantage of marketing protection provided by patents on the reformulated chemical entity or its method of manufacture, the Waxman-Hatch Act, or Orphan Drug regulations. The company focuses on unmet or under-served clinical needs in the areas of migraine prophylaxis, epilepsy and bipolar disorder, acute hypertensive crisis, chemotherapy induced nausea and vomiting, nocturnal incontinence and gastrotintestional disorders.
Crawford Pharmaceuticals is a leading supplier of dermatology products for a range of skin conditions. Crawford Pharmaceuticals Limited is a specialty pharmaceutical company dedicated to making effective dermatological treatments available to healthcare professionals and patients. By working with partner companies who are leaders in their respective fields and markets Crawford can offer innovative and valuable treatments across a range of dermatological conditions. Pharmaceutical products sales across major international markets are more than €250 billion of which dermatology products account for more than €8 billion. Crawford Healthcare is focusing efforts on developing domestic and international sales opportunities in this sector through organic growth and acquisition. Current key areas include Psoriasis, Eczema, Contact Dermatitis, Photodermatology and prevention of Photodamage. Current key areas include Acne, Contact Dermatitis, Eczema, Photodermatology, Psoriasis, Sun Protection and Vitiligo.
http://www.chxtechnologies.com
CHX Technologies is dedicated to the improvement of oral health and overall health. Our PrevoraTM Antibacterial Tooth Coating, already approved in Canada and Ireland, provides the dental profession with the first evidence-based therapy to prevent tooth decay in at-risk adults. CHX Technologies is undertaking one of the largest and most advanced clinical research and regulatory programs on new therapies for prevention of oral diseases, which can be markers for overall health. Through these efforts, we are committed to linking emerging science to everyday dental practice, and to informing both dental professionals and their patients on new preventive treatments for common dental diseases.
Valeo Pharma inc. is committed to provide health care professionals and patients with high quality specialty pharmaceuticals products. Whether it is through the acquisition of classic brands that continue to provide time-tested sought-after therapeutic benefits or our innovation products, Valeo Pharma is dedicated to bring quality products to life for the benefit of Canadians.
US WorldMeds is a closely held Delaware limited liability company, which was organized on March 23, 2001 to develop and sell affordable pharmaceutical products to help people worldwide. Its principal officers, friends, family and grants (Vogt Fund inaugural winner and Kentucky Science & Technology Corporation) have funded the business to date. US WorldMeds' key officers include: Chief Executive Officer: Paul Breckinridge "Breck" Jones, a Wharton MBA, who has founded or co-founded several successful businesses. Chief Scientific Officer: George Digenis, Ph.D., Professor Emeritus of Medicinal Chemistry and Pharmaceutics at the University of Kentucky College of Pharmacy. Vice President Regulatory Affairs: Jeff Staffa, Ph.D., a former FDA official and 20+ year industry veteran Vice President Clinical Research: Charles W. "Chuck" Gorodetzky, M.D., Ph.D., former Scientific Director and 20+ years at the NIDA Addiction Research Center in Lexington, KY, plus 20+ years leading industry clinical research efforts. Vice President Commercial Operations: H. Lee Warren, Jr., a 20-year industry veteran. Director Regulatory Affairs: Donald R. Peckels, a 35-year veteran in the US Rx drug pharmaceutical arena. Given our commitment to Research & Development, product efficacy, and end user satisfaction, it won't be long before US WorldMeds will be making more and more top quality generic choices available to you. We're looking forward to a significant future of offering access to safe, effective, affordable medications. US WorldMeds is eager to provide fairly priced pharmaceuticals that help people enjoy longer, healthier, happier lives.
Medical Futures Inc. is a niche pharmaceutical company that sells both pharmaceutical and natural therapeutic products into the gastrointestinal marketplace. Founded in 2000, this privately held company is dedicated to advancing the health of Canadians. Medical Futures Inc. in-licenses products for the Canadian market. We are actively researching new products for a variety of gastrointestinal disease states. Our lead product is a chemo preventative agent for reduction of colon polyp formation. This novel product will be marketed by Medical Futures Inc. in Canada and by partners in other parts of the world. Medical Futures Inc. is a leader in providing clinically proven natural therapeutic agents to consumers and physicians. Florastor, the lead product for Medical Futures Inc. has been used by over 80 countries for over 50 years. After 10 billion doses world wide, the clinical efficacy and safety record have been proven objectively.
Cebert has been established to provide psychotropic pharmaceutical products to better serve psychiatrists and their patients. The company's focus will primarily be directed at the psychiatric medical specialty. Though there are a number of pharmaceutical companies that have one or more products for the psychiatric practice, no company currently has its primary focus on this specialty. Cebert plans to concentrate its product portfolio and field sales force on serving psychiatric practices. Cebert's objective is to fill unmet needs for the psychiatric patient. Through the development of new, innovative psychopharmaceutical agents and the acquisition/licensing of existing proprietary psychotropic products, Cebert's objective is to be The Psychopharmaceutical Company. This can only be achieved through building, block-by-block, a solid foundation of products. Behind every successful sales and marketing company is a solid, aggressive, product development team that keeps a stream of new products coming. Fortunately, Cebert has excellent, experienced people to meet this challenge. Within pharmaceutical circles, new products are referred to as the "lifeblood" of the company. New products must be put into the sales team's hands on a regular basis. Management will continue to add new products that fit the strategy and will grow the Company. In 2006, it is anticipated that the major focus will be on marketing a new, innovative product indicated for the relief of panic disorder. Cebert believes that building a solid foundation of products and fielding an exceptional sales team will result in steady growth. The goals for Cebert are ambitious. The management team continues to seek opportunities to license and/or acquire other products for treating the broad spectrum of psychiatric disorders. Please visit the Cebert website frequently for information to learn about more new, innovative products.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory